Keywords: Antisoma, Novartis, Lung cancer, ASA404, Research

Antisoma plunges 72% after saying continuing late-stage NSCLC drug candidate development would be “futile”

Article | 29 March 2010

Print This

UK cancer drug developer Antisoma revealed this morning that the planned interim analysis of data from the ATTRACT-1 Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in